Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pharma partnership

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

Celgene building

FDA turns down Celgene’s filing for multiple sclerosis drug

The application needs additional pharmacology information according to the US agency

- PMLiVE

Ablynx reshuffles its board again

Dr Bo Jesper Hansen resigns from the Belgium biotech's board

Robert Freisen joins Ablynx

He will take the role of chief scientific officer, effective March 1

Sanofi reception

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

The offer comes at a 110% premium on the Belgian biopharma’s share price

Novo Nordisk target Ablynx reshuffles its board

Dr Bo Jesper Hensen has been elected as biopharma’s new chairman

- PMLiVE

Ablynx knocks-back Novo Nordisk’s second bid

Says the Danish pharma group “fundamentally undervalues” the company

- PMLiVE

Novo Nordisk makes improved €2.6bn offer for Ablynx

Goes back to the Belgian biopharma with a higher bid

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Teva launches personalised digital support for MS patients

Says its MS Care Programme is the first of its kind

- PMLiVE

Belgium’s Ablynx enters the US market

The biopharma firm's new subsidiary will be led by Daniel Schneider

- PMLiVE

Ablynx buoyant as lead antibody aces phase III trial

Caplacizumab met its primary endpoint and reduced aTTP-related death by 74%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links